Saphnelo approved in EU for treatment of moderate to severe systemic lupus erythematosus miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy. Saphnelo is the first biologic for SLE approved in .
Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosusSaphnelo is a first-in-class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosusAstraZeneca’s Saphnelo (anifrolumab) has been approved in the.